HSV-2 mRNA vaccine (Lifanda Biotechnology)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameHSV-2 mRNA vaccine (Lifanda Biotechnology)
Drug Alias NameⅡ型单纯疱疹病毒mRNA疫苗
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHerpes SimplexHerpes Genitalis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai Lifanda Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Lifanda Biotechnology Co LtdChangchun Bcht Biotechnology Co
Inactive CompaniesN/A
Active IndicationsHerpes SimplexHerpes Genitalis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A